1. Home
  2. MDGL
  3. MDGL News

Latest Madrigal Pharmaceuticals Inc. (MDGL) News on April 2, 2025

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?
MDGL

Insider Monkey

4 days ago

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

Exploring 3 High Growth Tech Stocks in the US Market
MDGL

Simply Wall St.

5 days ago

Exploring 3 High Growth Tech Stocks in the US Market

Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires
MDGL

Insider Monkey

15 days ago

Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
MDGL

GlobeNewswire

22 days ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now
MDGL

TipRanks

a month ago

Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
MDGL

TipRanks

a month ago

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

MDGL

MT Newswires

a month ago

B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236

MDGL

MT Newswires

a month ago

Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says

We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn
MDGL

Simply Wall St.

a month ago

We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn

High Growth Tech Stocks In US For February 2025
MDGL

Simply Wall St.

a month ago

High Growth Tech Stocks In US For February 2025

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...
MDGL

GuruFocus.com

a month ago

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

MDGL

Thomson Reuters StreetEvents

a month ago

Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
MDGL

Benzinga

a month ago

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

MDGL

MT Newswires

a month ago

Madrigal Pharmaceuticals Shares Jump After Q4 Beat, Release of New Data on Steatohepatitis Drug

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL

Zacks

a month ago

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Why Madrigal Pharmaceuticals Stock Is Soaring Today
MDGL

Motley Fool

a month ago

Why Madrigal Pharmaceuticals Stock Is Soaring Today

MDGL

MT Newswires

a month ago

Madrigal Pharmaceuticals Says Steatohepatitis Drug Shows 'Marked Reductions' in Patients' Liver Stiffness

MDGL

MT Newswires

a month ago

Sector Update: Health Care Stocks Decline Pre-Bell Wednesday

MDGL

MT Newswires

a month ago

Madrigal Pharmaceuticals' Q4 Net Loss Narrows, Revenue Tops Estimates

MDGL

Associated Press Finance

a month ago

Madrigal: Q4 Earnings Snapshot

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
MDGL

GlobeNewswire

a month ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
MDGL

GlobeNewswire

a month ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
MDGL

GlobeNewswire

a month ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
MDGL

GlobeNewswire

2 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

MDGL

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 01/28/2025

MDGL

MT Newswires

2 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $531,020, According to a Recent SEC Filing

Exploring Three High Growth Tech Stocks in the United States
MDGL

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks in the United States

MDGL

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 01/21/2025

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
MDGL

Motley Fool

3 months ago

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
MDGL

Zacks

3 months ago

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales

MDGL

MT Newswires

3 months ago

Update: Madrigal Pharmaceuticals Shares Decline After Posting Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million

Why Madrigal Pharmaceuticals Stock Is Sinking Today
MDGL

Motley Fool

3 months ago

Why Madrigal Pharmaceuticals Stock Is Sinking Today

MDGL

MT Newswires

3 months ago

Madrigal Pharmaceuticals Reports Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
MDGL

GlobeNewswire

3 months ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MDGL

GlobeNewswire

3 months ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Exploring Three High Growth Tech Stocks In The United States
MDGL

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks In The United States

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook
MDGL

Simply Wall St.

3 months ago

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook

Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities
MDGL

TipRanks

4 months ago

Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

MDGL

MT Newswires

4 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
MDGL

Motley Fool

4 months ago

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
MDGL

Zacks

4 months ago

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
MDGL

Insider Monkey

4 months ago

Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?

The first MASH drug could open the door for others — including GLP-1s
MDGL

Pharma Voice

4 months ago

The first MASH drug could open the door for others — including GLP-1s

John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
MDGL

GuruFocus.com

5 months ago

John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
MDGL

Zacks

5 months ago

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
MDGL

Motley Fool

5 months ago

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

5 Small Drug Stocks to Buy as Trump Gets Re-Elected
MDGL

Zacks

5 months ago

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

3 High Growth Tech Stocks Leading The US Market
MDGL

Simply Wall St.

5 months ago

3 High Growth Tech Stocks Leading The US Market

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

MDGL

MT Newswires

5 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing

MDGL

MT Newswires

5 months ago

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $236 From $194, Maintains Neutral Rating

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations
MDGL

GuruFocus.com

5 months ago

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
MDGL

TipRanks

5 months ago

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts
MDGL

Simply Wall St.

5 months ago

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts

Madrigal Pharmaceuticals stock jumps on MASH drug hopes
MDGL

Yahoo Finance Video

5 months ago

Madrigal Pharmaceuticals stock jumps on MASH drug hopes

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
MDGL

Investor's Business Daily

5 months ago

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

MDGL

MT Newswires

5 months ago

UBS Adjusts Price Target on Madrigal Pharmaceuticals to $441 From $411, Maintains Buy Rating

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
MDGL

Zacks

5 months ago

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...
MDGL

GuruFocus.com

5 months ago

Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...

MDGL

MT Newswires

5 months ago

Sector Update: Health Care

MDGL

MT Newswires

5 months ago

Madrigal Pharmaceuticals' Shares Rise After Reporting Narrower Q3 Loss

MDGL

Associated Press Finance

5 months ago

Madrigal: Q3 Earnings Snapshot

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
MDGL

Clinical Trials Arena

5 months ago

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra
MDGL

Insider Monkey

6 months ago

Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra

High Growth Tech Stocks To Watch In October 2024
MDGL

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In October 2024

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?
MDGL

Insider Monkey

6 months ago

Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?

MDGL

MT Newswires

7 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,551,490, According to a Recent SEC Filing

Exploring 3 High Growth Tech Stocks in the United States
MDGL

Simply Wall St.

7 months ago

Exploring 3 High Growth Tech Stocks in the United States

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
MDGL

GlobeNewswire

7 months ago

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Is Madrigal Pharmaceuticals Stock a Buy?
MDGL

Motley Fool

8 months ago

Is Madrigal Pharmaceuticals Stock a Buy?

John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc
MDGL

GuruFocus.com

8 months ago

John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
MDGL

Motley Fool

8 months ago

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock

Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected
MDGL

Pharmaceutical Technology

8 months ago

Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected

MDGL

MT Newswires

8 months ago

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating

MDGL

Thomson Reuters StreetEvents

8 months ago

Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
MDGL

Investor's Business Daily

8 months ago

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
MDGL

Zacks

8 months ago

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

MDGL

MT Newswires

8 months ago

Madrigal Pharmaceuticals Reports Q2 Revenue as Loss Widens; Shares Gain Pre-Bell

MDGL

Associated Press Finance

8 months ago

Madrigal: Q2 Earnings Snapshot

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
MDGL

GlobeNewswire

8 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal’s MASH drug launch gets off to a fast start
MDGL

BioPharma Dive

8 months ago

Madrigal’s MASH drug launch gets off to a fast start

Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
MDGL

Motley Fool

8 months ago

Is It Too Late to Buy Madrigal Pharmaceuticals Stock?

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
MDGL

GlobeNewswire

8 months ago

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Top Growth Stocks With High Insider Ownership In US For August 2024
MDGL

Simply Wall St.

8 months ago

Top Growth Stocks With High Insider Ownership In US For August 2024

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
MDGL

GlobeNewswire

8 months ago

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

MDGL

MT Newswires

9 months ago

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating

Unveiling Three US Growth Companies With High Insider Ownership
MDGL

Simply Wall St.

9 months ago

Unveiling Three US Growth Companies With High Insider Ownership

Is Madrigal Pharmaceuticals a Millionaire Maker?
MDGL

Motley Fool

9 months ago

Is Madrigal Pharmaceuticals a Millionaire Maker?

MDGL

MT Newswires

9 months ago

Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating

Is Madrigal Pharmaceuticals Stock a Buy?
MDGL

Motley Fool

9 months ago

Is Madrigal Pharmaceuticals Stock a Buy?

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
MDGL

Motley Fool

10 months ago

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

Where Will Madrigal Pharmaceuticals Be in 3 Years?
MDGL

Motley Fool

10 months ago

Where Will Madrigal Pharmaceuticals Be in 3 Years?

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
MDGL

Investor's Business Daily

10 months ago

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade

Share on Social Networks: